Company intelligence / Profile preview

āshibio

Brisbane, California, United Statesashibio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

āshibio has exited stealth mode with $40M in seed and Series A funding. Its lead asset, andecaliximab, will enter a Phase 2/3 trial for FOP. The company aims to address severe unmet needs in rare bone/connective tissue diseases using innovative therapeutic approaches. No clinical results have been published yet as trials are about to begin

Therapeutic areas: RheumatologyRare Diseases
Modalities: biologics/monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

andecaliximab

Partnerships

MPM BioImpact (lead investor)Agent CapitalYK BioventuresMirae Asset Venture Investment

Beyond the preview

Go deeper on āshibio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on āshibio.

Explore the full profile